-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
J.W. Cole Advisors Inc. Has $88,000 Stock Holdings in VBI Vaccines Inc. (NASDAQ:VBIV)
J.W. Cole Advisors Inc. Has $88,000 Stock Holdings in VBI Vaccines Inc. (NASDAQ:VBIV)
J.W. Cole Advisors Inc. trimmed its position in VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) by 27.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,100 shares of the biopharmaceutical company's stock after selling 20,000 shares during the period. J.W. Cole Advisors Inc.'s holdings in VBI Vaccines were worth $88,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of the company. E Fund Management Co. Ltd. raised its holdings in VBI Vaccines by 98.1% during the 1st quarter. E Fund Management Co. Ltd. now owns 53,148 shares of the biopharmaceutical company's stock worth $88,000 after buying an additional 26,320 shares during the period. GSA Capital Partners LLP acquired a new stake in VBI Vaccines during the 4th quarter worth approximately $257,000. Nisa Investment Advisors LLC raised its holdings in VBI Vaccines by 1,099.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 126,800 shares of the biopharmaceutical company's stock worth $210,000 after buying an additional 116,230 shares during the period. Grimes & Company Inc. raised its holdings in VBI Vaccines by 19.6% during the 1st quarter. Grimes & Company Inc. now owns 281,077 shares of the biopharmaceutical company's stock worth $467,000 after buying an additional 46,116 shares during the period. Finally, Wealthsource Partners LLC acquired a new stake in VBI Vaccines during the 1st quarter worth approximately $238,000. 39.96% of the stock is currently owned by institutional investors and hedge funds.
Get VBI Vaccines alerts:VBI Vaccines Price Performance
NASDAQ VBIV opened at $0.73 on Friday. The company has a quick ratio of 2.19, a current ratio of 2.29 and a debt-to-equity ratio of 0.20. VBI Vaccines Inc. has a 12-month low of $0.64 and a 12-month high of $3.49. The company has a market capitalization of $189.22 million, a PE ratio of -1.88 and a beta of 1.86. The firm's 50 day moving average is $0.93 and its 200-day moving average is $1.09.
VBI Vaccines (NASDAQ:VBIV – Get Rating) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.11). VBI Vaccines had a negative net margin of 15,391.36% and a negative return on equity of 75.37%. The business had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.70 million. Equities research analysts anticipate that VBI Vaccines Inc. will post -0.37 earnings per share for the current fiscal year.Analyst Ratings Changes
Separately, Raymond James dropped their target price on shares of VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating on the stock in a report on Tuesday, August 9th.
About VBI Vaccines
(Get Rating)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
See Also
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
J.W. Cole Advisors Inc. trimmed its position in VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) by 27.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,100 shares of the biopharmaceutical company's stock after selling 20,000 shares during the period. J.W. Cole Advisors Inc.'s holdings in VBI Vaccines were worth $88,000 at the end of the most recent quarter.
根據J.W.Cole Advisors Inc.最近提交給美國證券交易委員會(美國證券交易委員會)的13F文件，該公司在第一季度將其在VBI疫苗公司(VBI Vaccines Inc.)的頭寸削減了27.4%。在此期間，該公司出售了20,000股票，擁有這家生物製藥公司53,100股票。截至最近一個季度末，J.W.Cole Advisors Inc.持有的VBI疫苗價值8.8萬美元。
A number of other hedge funds have also modified their holdings of the company. E Fund Management Co. Ltd. raised its holdings in VBI Vaccines by 98.1% during the 1st quarter. E Fund Management Co. Ltd. now owns 53,148 shares of the biopharmaceutical company's stock worth $88,000 after buying an additional 26,320 shares during the period. GSA Capital Partners LLP acquired a new stake in VBI Vaccines during the 4th quarter worth approximately $257,000. Nisa Investment Advisors LLC raised its holdings in VBI Vaccines by 1,099.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 126,800 shares of the biopharmaceutical company's stock worth $210,000 after buying an additional 116,230 shares during the period. Grimes & Company Inc. raised its holdings in VBI Vaccines by 19.6% during the 1st quarter. Grimes & Company Inc. now owns 281,077 shares of the biopharmaceutical company's stock worth $467,000 after buying an additional 46,116 shares during the period. Finally, Wealthsource Partners LLC acquired a new stake in VBI Vaccines during the 1st quarter worth approximately $238,000. 39.96% of the stock is currently owned by institutional investors and hedge funds.
其他一些對衝基金也調整了對該公司的持股。易方達基金管理有限公司在第一季度增持VBI疫苗98.1%。易方達基金管理有限公司現在持有53,148股這家生物製藥公司的股票，價值88,000美元，在此期間又購買了26,320股。GSA Capital Partners LLP在第四季度收購了VBI疫苗公司的新股份，價值約25.7萬美元。NISA Investment Advisors LLC在第一季度將其在VBI疫苗的持有量增加了1099.6%。NISA Investment Advisors LLC現在持有這家生物製藥公司的12.68萬股票，價值21萬美元，在此期間又購買了116,230股票。Grimes&Company Inc.在第一季度將其在VBI疫苗公司的持股增加了19.6%。Grimes&Company Inc.現在持有281,077股這家生物製藥公司的股票，價值467,000美元，在此期間又購買了46,116股。最後，Wealthsource Partners LLC在第一季度收購了VBI疫苗公司價值約23.8萬美元的新股份。該公司39.96%的股票目前由機構投資者和對衝基金持有。
VBI Vaccines Price Performance
VBI疫苗的價格表現
NASDAQ VBIV opened at $0.73 on Friday. The company has a quick ratio of 2.19, a current ratio of 2.29 and a debt-to-equity ratio of 0.20. VBI Vaccines Inc. has a 12-month low of $0.64 and a 12-month high of $3.49. The company has a market capitalization of $189.22 million, a PE ratio of -1.88 and a beta of 1.86. The firm's 50 day moving average is $0.93 and its 200-day moving average is $1.09.
納斯達克VBIV上週五開盤報0.73美元。該公司的速動比率為2.19，流動比率為2.29，債務權益比為0.20。VBI疫苗公司的股價為0.64美元的12個月低點和3.49美元的12個月高位。該公司市值為1.8922億美元，市盈率為-1.88，貝塔係數為1.86。該公司的50日移動均線切入位在0.93美元，200日移動均線切入位在1.09美元。
Analyst Ratings Changes
分析師評級發生變化
Separately, Raymond James dropped their target price on shares of VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating on the stock in a report on Tuesday, August 9th.
另外，雷蒙德·詹姆斯在8月9日週二的一份報告中將VBI疫苗的目標價從6.00美元下調至5.00美元，並將該股的評級定為“強力買入”。
About VBI Vaccines
關於VBI疫苗
(Get Rating)
(獲取評級)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
VBI疫苗公司是一家生物製藥公司，開發和銷售用於治療傳染病和免疫腫瘤學的疫苗。該公司提供一種預防性乙肝疫苗Sci-B-Vac。它還參與VBI-2601(BRII-179)的開發，VBI-2601(BRII-179)是治療慢性乙肝感染的免疫治療候選藥物。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 免費獲取StockNews.com關於VBI疫苗的研究報告(VBIV)
- 斯蒂爾凱斯的收益説明瞭他重返辦公室的原因嗎？
- 這些機構持有達頓餐飲國際公司的股份
- 這三大股利支付者也擁有強勁的價格增長
- 住房建設的黃金時代已經結束了嗎？
- 天然氣價格繼續回升，這些股票應該會受益
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到VBI疫苗的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對VBI疫苗和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧